Vyne Therapeutics Stock Current Liabilities
| VYNE Stock | USD 2.89 0.06 2.03% |
Vyne Therapeutics fundamentals help investors to digest information that contributes to Vyne Therapeutics' financial success or failures. It also enables traders to predict the movement of Vyne Stock. The fundamental analysis module provides a way to measure Vyne Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vyne Therapeutics stock.
At present, Vyne Therapeutics' Non Current Liabilities Other is projected to increase significantly based on the last few years of reporting. Vyne | Current Liabilities |
Vyne Therapeutics Company Current Liabilities Analysis
Vyne Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Vyne Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Vyne Therapeutics is extremely important. It helps to project a fair market value of Vyne Stock properly, considering its historical fundamentals such as Current Liabilities. Since Vyne Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vyne Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vyne Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Vyne Current Liabilities Historical Pattern
Today, most investors in Vyne Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vyne Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Vyne Therapeutics current liabilities as a starting point in their analysis.
Vyne Therapeutics Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Vyne Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Vyne Therapeutics has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Vyne Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vyne Therapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vyne Therapeutics could also be used in its relative valuation, which is a method of valuing Vyne Therapeutics by comparing valuation metrics of similar companies.Vyne Therapeutics is currently under evaluation in current liabilities category among its peers.
Vyne Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Vyne Therapeutics from analyzing Vyne Therapeutics' financial statements. These drivers represent accounts that assess Vyne Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vyne Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 157.5M | 204.9M | 52.5M | 8.6M | 9.9M | 9.4M | |
| Enterprise Value | 127.4M | 182.1M | 10.6M | (22.7M) | (26.1M) | (24.8M) |
Vyne Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vyne Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vyne Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Vyne Fundamentals
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.35 | ||||
| Operating Margin | (52.51) % | ||||
| Current Valuation | (26.55 M) | ||||
| Shares Outstanding | 14.75 M | ||||
| Shares Owned By Insiders | 8.31 % | ||||
| Shares Owned By Institutions | 56.03 % | ||||
| Number Of Shares Shorted | 82.56 K | ||||
| Price To Book | 0.70 X | ||||
| Price To Sales | 88.27 X | ||||
| Revenue | 424 K | ||||
| Gross Profit | 477 K | ||||
| EBITDA | (29.26 M) | ||||
| Net Income | (28.45 M) | ||||
| Cash And Equivalents | 42.81 M | ||||
| Cash Per Share | 0.74 X | ||||
| Total Debt | 214 K | ||||
| Current Ratio | 7.60 X | ||||
| Book Value Per Share | 6.29 X | ||||
| Cash Flow From Operations | (25.34 M) | ||||
| Short Ratio | 1.23 X | ||||
| Earnings Per Share | 1.72 X | ||||
| Target Price | 5.58 | ||||
| Number Of Employees | 10 | ||||
| Beta | 1.35 | ||||
| Market Capitalization | 44.25 M | ||||
| Total Asset | 97.69 M | ||||
| Retained Earnings | (691.34 M) | ||||
| Working Capital | 88.42 M | ||||
| Net Asset | 97.69 M |
About Vyne Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vyne Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vyne Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vyne Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vyne Therapeutics is a strong investment it is important to analyze Vyne Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vyne Therapeutics' future performance. For an informed investment choice regarding Vyne Stock, refer to the following important reports:Check out Vyne Therapeutics Piotroski F Score and Vyne Therapeutics Altman Z Score analysis. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.72 | Revenue Per Share 0.016 | Quarterly Revenue Growth 0.467 | Return On Assets (0.35) | Return On Equity (0.60) |
The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.